about
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents.Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfilzomib-resistant multiple myeloma cells and high-risk multiple myeloma patients.DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.The proteasome and proteasome inhibitors in multiple myeloma.Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.BAFF is involved in macrophage-induced bortezomib resistance in myeloma.Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.Effects of microRNA-20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway.Clinical impact of serum soluble SLAMF7 in multiple myeloma
P2860
Q38671390-C71F974E-36E3-45C1-A55A-DB8553C07CFEQ41545464-FECC6B91-F017-4ED1-9D3D-19C296E8FFD6Q41548439-B1FAA5C5-5BEC-478A-A30B-2D75336419FBQ41559549-C0D288F9-6E76-443B-A72E-CDDF23FB6A79Q42022337-D6053635-A579-4895-A2AD-B296FD3EA41BQ45914413-E386F112-30C8-41AA-9C11-CB3F6B5F260BQ47149175-436F2BF9-F9D2-4512-A656-E52DA6B4C59CQ47329036-C70D5528-8CF3-4650-B38D-2FE3E2458B5BQ47339695-00DAB5D3-224D-48BF-871F-E473EE07231DQ47381020-4839D0F8-763E-47DE-B919-842BBA047DCCQ47630577-95ABE4FA-E741-46A4-A61D-6E7442A232BEQ47669883-1E84EFE9-0E93-4F93-AA3C-AADB6381CCECQ50036381-24C90396-589A-40E1-9B56-948D1BB7F794Q52682394-D41E4D69-5C74-4B24-8CC4-D7D7E6D35FC5Q55362922-1E0AAB0F-2529-4C21-993C-3483E3AB416FQ58582611-C748DDE4-402F-4D3C-BAE2-F758C3E66445
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Progress and Paradigms in Multiple Myeloma.
@en
Progress and Paradigms in Multiple Myeloma.
@nl
type
label
Progress and Paradigms in Multiple Myeloma.
@en
Progress and Paradigms in Multiple Myeloma.
@nl
prefLabel
Progress and Paradigms in Multiple Myeloma.
@en
Progress and Paradigms in Multiple Myeloma.
@nl
P2860
P1476
Progress and Paradigms in Multiple Myeloma.
@en
P2093
Kenneth C Anderson
P2860
P304
P356
10.1158/1078-0432.CCR-16-0625
P407
P577
2016-11-01T00:00:00Z